Both an Open Label Extension (OLE) and an Expanded Access Program (EAP) can be used to provide continued treatment access after phase 3 clinical trials have ended.

To help companies understand both programs and consider which would be the best option for them, we have created a table outlining the main differences between an OLE and an EAP.

Please complete the form to the right to download the resource.